{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:55:14Z","timestamp":1791338114396,"version":"4.3.1"},"reference-count":59,"publisher":"Georg Thieme Verlag KG","issue":"10","license":[{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Spinal muscular atrophy (SMA) is a genetic neuromuscular progressive disorder that is currently treatable. The sooner the disease-modifying therapies are started, the better the prognosis. Newborn screening for SMA, which is already performed in many countries, has been scheduled to begin in the near future. The development of a well-organized program is paramount to achieve favorable outcomes for the child who is born with the disease and for the costs involved in health care. We herein present a review paper hoping to point out that SMA neonatal screening is urgent and will not increase the cost of its care.<\/jats:p>","DOI":"10.1055\/s-0044-1791201","type":"journal-article","created":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T22:31:11Z","timestamp":1728858671000},"page":"001-009","source":"Crossref","is-referenced-by-count":4,"title":["Why should a 5q spinal muscular atrophy neonatal screening program be started?"],"prefix":"10.1055","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1232-5896","authenticated-orcid":false,"given":"Michele Michelin","family":"Becker","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre, Unidade de Neurologia Pedi\u00e1trica, Departamento de Pediatria, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8006-9435","authenticated-orcid":false,"given":"Fl\u00e1via","family":"Nardes","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Instituto de Puericultura e Pediatria Martag\u00e3o Gesteira, Departamento de Pediatria, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-4774","authenticated-orcid":false,"given":"Tamara","family":"Dangouloff","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Li\u00e8ge, Centre Hospitalier Universitaire de Li\u00e8ge, Centre de R\u00e9f\u00e9rence des Maladies Neuromusculaires, Service de P\u00e9diatrie, Li\u00e8ge, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-4061","authenticated-orcid":false,"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[{"name":"University of Oxford, MDUK Neuromuscular Centre, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-4354","authenticated-orcid":false,"given":"Alexandra Prufer de Queiroz Campos","family":"Araujo","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Instituto de Puericultura e Pediatria Martag\u00e3o Gesteira, Departamento de Pediatria, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-1491","authenticated-orcid":false,"given":"Juliana","family":"Gurgel-Giannetti","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Pediatria, Belo Horizonte MG, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,10,13]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/JND-221577","article-title":"Newbornscreening SMA - From Pilot Project to Nationwide Screening in Germany","volume":"10","author":"W M\u00fcller-Felber","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"03","key":"ref2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/ijns9030035","article-title":"Is Our Newborn Screening Working Well? A Literature Review of Quality Requirements for Newborn Blood Spot Screening (NBS) Infrastructure and Procedures","volume":"9","author":"B Odenwald","year":"2023","journal-title":"Int J Neonatal Screen"},{"issue":"03","key":"ref4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","article-title":"New treatments in spinal muscular atrophy: an overview of currently available data","volume":"21","author":"S Ramdas","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"07","key":"ref5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/genes14071377","article-title":"Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening-A Systematic Review","volume":"14","author":"K Aragon-Gawinska","year":"2023","journal-title":"Genes (Basel)"},{"issue":"06","key":"ref6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/jmg.15.6.409","article-title":"Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy","volume":"15","author":"J Pearn","year":"1978","journal-title":"J Med Genet"},{"issue":"01","key":"ref7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"E A Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"issue":"01","key":"ref8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"M D Mailman","year":"2002","journal-title":"Genet Med"},{"issue":"04","key":"ref9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal muscular atrophy: in the challenge lies a solution","volume":"44","author":"B Wirth","year":"2021","journal-title":"Trends Neurosci"},{"issue":"9630","key":"ref10","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"M R Lunn","year":"2008","journal-title":"Lancet"},{"issue":"05","key":"ref11","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1212\/NXG.0000000000000505","article-title":"Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy","volume":"6","author":"R H Mendon\u00e7a","year":"2020","journal-title":"Neurol Genet"},{"issue":"578","key":"ref12","doi-asserted-by":"publisher","first-page":"eabb6871","DOI":"10.1126\/scitranslmed.abb6871","article-title":"Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA","volume":"13","author":"L Kong","year":"2021","journal-title":"Sci Transl Med"},{"issue":"16","key":"ref13","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy","volume":"17","author":"S Kariya","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"07","key":"ref14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/hmg\/ddm367","article-title":"Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy","volume":"17","author":"L M Murray","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"05","key":"ref15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"B T Darras","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"06","key":"ref16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1212\/WNL.0000000000007836","article-title":"Discrepancy in redetermination of SMN2 copy numbers in children with SMA","volume":"93","author":"D C Schorling","year":"2019","journal-title":"Neurology"},{"issue":"06","key":"ref17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"S J Kolb","year":"2017","journal-title":"Ann Neurol"},{"issue":"09","key":"ref18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"R S Finkel","year":"2014","journal-title":"Neurology"},{"issue":"01","key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care","volume":"7","author":"D C Schorling","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"09","key":"ref20","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/ijms21093297","article-title":"New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?","volume":"21","author":"T H Chen","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"07","key":"ref21","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00431-022-04470-3","article-title":"Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening","volume":"181","author":"M Pane","year":"2022","journal-title":"Eur J Pediatr"},{"issue":"11","key":"ref22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"D C De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"02","key":"ref23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"T O Crawford","year":"2023","journal-title":"Muscle Nerve"},{"issue":"07","key":"ref24","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"K A Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"07","key":"ref25","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"K A Strauss","year":"2022","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"100899","DOI":"10.1016\/j.spen.2021.100899","article-title":"Spinal Muscular Atrophy Treatments, Newborn Screening, and the Creation of a Neurogenetics Urgency","volume":"38","author":"R J Butterfield","year":"2021","journal-title":"Semin Pediatr Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.07.087","article-title":"Impact of disease modifying treatment by three months of life on swallowing in Spinal Muscular Atrophy Type I- Poster 206 World Muscle Society","volume":"33","author":"K McGrattan","year":"2023","journal-title":"Neuromuscular Disorders"},{"issue":"07","key":"ref30","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/brain\/awac125","article-title":"Pre-symptomatic spinal muscular atrophy: a proposed nosology","volume":"145","author":"R S Finkel","year":"2022","journal-title":"Brain"},{"issue":"08","key":"ref31","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","article-title":"Time is motor neuron: therapeutic window and its correlation with pathogenic mechanisms in spinal muscular atrophy","volume":"55","author":"A Govoni","year":"2018","journal-title":"Mol Neurobiol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/DNND.S246907","article-title":"Advances in Newborn Screening and Presymptomatic Diagnosis of Spinal Muscular Atrophy","volume":"10","author":"M J\u0119drzejowska","year":"2020","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"02","key":"ref33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening","volume":"5","author":"J Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised Recommendations for the Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening","volume":"7","author":"J Glascock","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"07","key":"ref35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/jmg-2022-108873","article-title":"Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis","volume":"60","author":"E Abiusi","year":"2023","journal-title":"J Med Genet"},{"issue":"01","key":"ref36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years","volume":"16","author":"K Vill","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"03","key":"ref37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JND-220789","article-title":"Spinal Muscular Atrophy - Is Newborn Screening Too Late for Children with Two SMN2 Copies?","volume":"9","author":"O Schwartz","year":"2022","journal-title":"J Neuromuscul Dis"},{"issue":"01","key":"ref38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","article-title":"Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments","volume":"16","author":"T Dangouloff","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.nmd.2023.11.013","article-title":"Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium","volume":"34","author":"T Dangouloff","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.jval.2020.04.805","article-title":"PMU 30 Cost-effectiveness analysis of newborn screening for spinal muscular atrophy (SMA) in the United States","volume":"23","author":"R Arjunji","year":"2020","journal-title":"Value Health"},{"issue":"01","key":"ref41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/dmcn.15286","article-title":"Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening","volume":"65","author":"T Dangouloff","year":"2023","journal-title":"Dev Med Child Neurol"},{"issue":"04","key":"ref42","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40120-023-00489-2","article-title":"Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England","volume":"12","author":"D Weidlich","year":"2023","journal-title":"Neurol Ther"},{"issue":"03","key":"ref43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/ijns8030045","article-title":"Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency","volume":"8","author":"S TF Shih","year":"2022","journal-title":"Int J Neonatal Screen"},{"issue":"10","key":"ref44","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jval.2022.06.010","article-title":"Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands","volume":"25","author":"R Velikanova","year":"2022","journal-title":"Value Health"},{"issue":"04","key":"ref46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2471\/BLT.07.050112","article-title":"Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years","volume":"86","author":"A Andermann","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"02","key":"ref47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"E Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"03","key":"ref48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"R S Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"08","key":"ref49","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"C H Wang","year":"2007","journal-title":"J Child Neurol"},{"issue":"01","key":"ref52","doi-asserted-by":"publisher","first-page":"19922","DOI":"10.1038\/s41598-021-99496-2","article-title":"Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium","volume":"11","author":"F Boemer","year":"2021","journal-title":"Sci Rep"},{"issue":"01","key":"ref53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.nmd.2019.11.002","article-title":"244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands","volume":"30","author":"T Dangouloff","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"06","key":"ref54","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go","volume":"31","author":"T Dangouloff","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"02","key":"ref55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/ijns7020026","article-title":"Massachusetts' Findings from Statewide Newborn Screening for Spinal Muscular Atrophy","volume":"7","author":"J E Hale","year":"2021","journal-title":"Int J Neonatal Screen"},{"issue":"03","key":"ref56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S2352-4642(22)00342-X","article-title":"Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study","volume":"7","author":"D S Kariyawasam","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"01","key":"ref57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ijns7010020","article-title":"A Voluntary Statewide Newborn Screening Pilot for Spinal Muscular Atrophy: Results from Early Check","volume":"7","author":"K S Kucera","year":"2021","journal-title":"Int J Neonatal Screen"},{"issue":"14","key":"ref58","doi-asserted-by":"publisher","first-page":"e1527","DOI":"10.1212\/WNL.0000000000200986","article-title":"Newborn Screening for Spinal Muscular Atrophy in New York State: Clinical Outcomes From the First 3 Years","volume":"99","author":"B H Lee","year":"2022","journal-title":"Neurology"},{"issue":"06","key":"ref59","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3233\/JND-221561","article-title":"California's experience with SMA newborn screening: A successful path to early intervention","volume":"9","author":"J Matteson","year":"2022","journal-title":"J Neuromuscul Dis"},{"issue":"03","key":"ref60","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/ijns9030042","article-title":"Alberta Spinal Muscular Atrophy Newborn Screening-Results from Year 1 Pilot Project","volume":"9","author":"F Niri","year":"2023","journal-title":"Int J Neonatal Screen"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S0140-6736(23)01281-3","article-title":"Universal newborn screening for spinal muscular atrophy in Ukraine","volume":"402","author":"N Olkhovych","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"ref62","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.3390\/genes14122211","article-title":"Newborn Screening for Spinal Muscular Atrophy: A 2.5-Year Experience in Hyogo Prefecture, Japan","volume":"14","author":"S Sonehara","year":"2023","journal-title":"Genes (Basel)"},{"issue":"04","key":"ref63","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10545-007-0650-7","article-title":"Newborn screening: a national public health programme in Brazil","volume":"30","author":"T M de Carvalho","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"03","key":"ref67","doi-asserted-by":"publisher","first-page":"e20230126","DOI":"10.1590\/1678-4685-GMB-2023-0126","article-title":"Neonatal screening for spinal muscular atrophy: A pilot study in Brazil","volume":"46","author":"A B Oliveira Netto","year":"2023","journal-title":"Genet Mol Biol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.nmd.2023.12.008","article-title":"270th ENMC International Workshop: Consensus for SMN2 genetic analysis in SMA patients 10-12 March, 2023, Hoofddorp, the Netherlands","volume":"34","author":"E Abiusi","year":"2024","journal-title":"Neuromuscul Disord"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1791201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:15:42Z","timestamp":1730808942000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1791201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,7,4]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["s00441791201"],"URL":"https:\/\/doi.org\/10.1055\/s-0044-1791201","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}